Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy

Prostate Cancer and Prostatic Diseases volume 16, pages 271–276 (2013)Cite this article

Subjects

Abstract

Background:

Accumulating evidence suggests that obesity is associated with tumor progression in prostate cancer (PCa) patients after radical prostatectomy (RP). We conducted a retrospective multicenter study to determine the effect of body mass index (BMI) on the clinicopathological characteristics and biochemical recurrence of PCa in Japanese men who underwent RP.

Methods:

The medical records of 1257 men with PCa treated by RP without neoadjuvant therapy at four medical institutes between 2001 and 2009 were retrospectively reviewed. Patients were categorized into four groups using the World Health Organization (WHO) BMI classification and BMI quartiles. Associations of the various BMI categories with clinicopathological characteristics and biochemical recurrences were statistically evaluated. Biochemical recurrence was defined as a PSA level of >0.2 ng ml–1.

Results:

Of the 1257 patients, 230 (18.3%) experienced biochemical recurrence during the median follow-up period of 49 months. The median BMI was 23.8 kg m–2, and 1.4% patients were underweight, 65.4% were of normal weight, 30.9% were overweight and 2.4% were obese (WHO classification). Preoperative PSA levels and PSA density (PSAD) tended to decrease as BMI increased. Pathological characteristics did not differ significantly among BMI categories. As per the WHO classification and quartile categories, biochemical recurrence rate was comparable among the BMI groups. After adjusting for other pre- and postoperative covariables, multivariate Cox proportional hazards analysis revealed that a high BMI did not have an independent impact on biochemical recurrence-free survival.

Conclusions:

Underweight Japanese PCa patients treated by RP had higher preoperative PSA levels and PSAD. High BMI was not associated with adverse pathological findings or increased biochemical recurrence rate in Japanese PCa patients treated with RP. Racial differences may exist in the relationship between obesity and outcomes of RP in PCa patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638.

    Article  Google Scholar 

  2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M . Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–578.

    Article  Google Scholar 

  3. MacInnis RJ, English DR . Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989–1003.

    Article  Google Scholar 

  4. Discacciati A, Orsini N, Wolk A . Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23: 1665–1671.

    Article  CAS  PubMed  Google Scholar 

  5. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275–2280.

    Article  PubMed  Google Scholar 

  6. Parsons JK, Sarma AV, McVary K, Wei JT . Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009; 182 (Suppl 6): S27–S31.

    Article  PubMed  Google Scholar 

  7. Culp S, Porter M . The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int 2009; 104: 1457–1461.

    Article  PubMed  Google Scholar 

  8. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001; 58: 723–728.

    Article  CAS  PubMed  Google Scholar 

  9. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004; 22: 446–453.

    Article  PubMed  Google Scholar 

  10. Freedland SJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, Trock B et al. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 2004; 172: 520–524.

    Article  PubMed  Google Scholar 

  11. Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW et al. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 2005; 11: 2883–2888.

    Article  CAS  PubMed  Google Scholar 

  12. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 2005; 66: 1060–1065.

    Article  PubMed  Google Scholar 

  13. Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 2007; 177: 102–106.

    Article  PubMed  Google Scholar 

  14. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW . Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009; 12: 259–263.

    Article  CAS  PubMed  Google Scholar 

  15. Ploussard G, de la Taille A, Bayoud Y, Durand X, Terry S, Xylinas E et al. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol 2012; 61: 356–362.

    Article  PubMed  Google Scholar 

  16. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 2008; 72: 1246–1251.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC Jr., Amling CL et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2009; 115: 5263–5271.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lee SE, Lee WK, Jeong MS, Abdullajanov M, Kim DS, Park HZ et al. Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men? BJU Int 2011; 107: 1250–1255.

    Article  PubMed  Google Scholar 

  19. Kok DE, van Roermund JG, Aben KK, van de Luijtgaarden MW, Karthaus HF, van Vierssen Trip OB et al. Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer. World J Urol 2011; 29: 695–701.

    Article  CAS  PubMed  Google Scholar 

  20. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM . Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549–1555.

    Article  CAS  Google Scholar 

  21. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer 2006; 107: 521–529.

    Article  PubMed  Google Scholar 

  22. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–163.

    Article  Google Scholar 

  23. Hisasue S, Yanase M, Shindo T, Iwaki H, Fukuta F, Nishida S et al. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy. Jpn J Clin Oncol 2008; 38: 129–133.

    Article  PubMed  Google Scholar 

  24. Komaru A, Kamiya N, Suzuki H, Endo T, Takano M, Yano M et al. Implications of body mass index in Japanese patients with prostate cancer who had undergone radical prostatectomy. Jpn J Clin Oncol 2010; 40: 353–359.

    Article  PubMed  Google Scholar 

  25. Isbarn H, Jeldres C, Budaus L, Salomon G, Schlomm T, Steuber T et al. Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series. Urology 2009; 73: 615–619.

    Article  PubMed  Google Scholar 

  26. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103: 1092–1095.

    Article  PubMed  Google Scholar 

  27. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001–2004. Cancer Epidemiology Biomarkers Prevention 2007; 16: 70–76.

    Article  CAS  Google Scholar 

  28. Freedland SJ, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175: 500–504.

    Article  PubMed  Google Scholar 

  29. Park SG, Choi HC, Cho B, Kwon YM, Kwon HT, Park JH . Effect of central obesity on prostate specific antigen measured by computerized tomography: related markers and prostate volume. J Urol 2012; 187: 1589–1593.

    Article  CAS  PubMed  Google Scholar 

  30. Bryniarski P, Paradysz A, Fryczkowski M . PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monitor 2011; 17: CR104–CR109.

    Article  Google Scholar 

  31. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB et al. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prevention Research (Philadelphia, PA) 2011; 4: 544–551.

    Article  Google Scholar 

  32. Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Wolk A . Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer 2011; 105: 1061–1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Akita University School of Medicine, Akita, Japan

    S Narita, N Tsuchiya & T Habuchi

  2. Michinoku Japan Urologicl Cancer Study Group (MJUCSG),

    S Narita, K Mitsuzuka, T Yoneyama, N Tsuchiya, T Koie, N Kakoi, S Kawamura, Y Kaiho, C Ohyama, T Tochigi, T Habuchi & Y Arai

  3. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    K Mitsuzuka, Y Kaiho & Y Arai

  4. Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan

    T Yoneyama, T Koie & C Ohyama

  5. Department of Urology, Miyagi Cancer Center, Natori, Japan

    N Kakoi, S Kawamura & T Tochigi

  6. Department of Medical Sciences and Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan

    T Yamaguchi

Authors
  1. S Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Mitsuzuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Koie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Kakoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Kaiho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Tochigi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. T Habuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Y Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Habuchi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Narita, S., Mitsuzuka, K., Yoneyama, T. et al. Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 16, 271–276 (2013). https://doi.org/10.1038/pcan.2013.16

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2013.16

Keywords

This article is cited by

Search

Advanced search

Quick links